@DrNikitaMehra @RahulBanerjeeMD @BloodJournal Important finding. What dose you recommend?

@drakhilkapoor1 @VanitaNoronha @bkmmishra @TMC_Varanasi @NarjustFlorezMD @Bipinesh @dranuj16 @ASCO @IASLC @DrSanjayPopat @DrJNaidoo @LungConnectIN @myESMO @oncodaily @SuyogCancer @JenniferCKing @StephenVLiu Congratulations. You continue to inspire.

@bhargava611 @AnantRamaswamy @drakhilkapoor1 @SuyogCancer Is there any data on PARPi in such setting as maintainence?

@ElonMNews @Amolpatel_dr Yes

@todrashish @PTarantinoMD How do you sequence, sir? Post cdk4/6i and AI?

@SuyogCancer @myESMO What about interlace? Any role of NACT fb CTRT?

@drakhilkapoor1 @ASCOPost @Bipinesh @csoncol @SuyogCancer @oncodaily @OncoAlert @GlobOncX Ldnivo plus TMC works in platinum sensitive, too. Knowing that we can use TMC only once what is best partner...Pacli carbo or LDNivo?

@drakhilkapoor1 @ASCOPost @Bipinesh @csoncol @SuyogCancer Important data. Congratulations. Where to place it now knowing the data of ld nivo and omct? Can you give doses and schedule of all drugs, please? I find weekly pacli carbo with omct bit difficult from toxicity perspective.

@DrVijayPatil11 @VanitaNoronha @Nandinimenon18 @SuyogCancer @Amolpatel_dr @SewantiLimaye @ASCO Congratulations. Can we stop Nivo or OMCT after 2 year timepoint in a patient?

@dramandeeparora @drgaganprakash @TataMemorial @MahendraTMH @AdityaBagrodia @siadaneshmand @YAUpenile_tesCa @CDFankhauser @GTumors @VedangMurthy @docpriyamvada @AmitJos98615230 We sometimes face residual RP plus extra RP disease(liver,lung) radiologically with normal tumor markers. What should be the management 1. If unresectable Extra RP disease? 2. Very morbid RP resection with resectable Extra RP disease?

@DrVijayPatil11 @docdcruz @henson_md @ASCOPost @VanitaNoronha @tmhmedoncalumni @DrEzraCohen @H_N_C_I_G Any data on 3 days tpf, which I see so routinely used even in fit patients for fear of toxicity? How can we improve on TPF as toxicities and cost of TPF is higher? Pacli Carbo OMCT LD nivo OMCT Regimens to ponder on.

@DrVijayPatil11 @docdcruz @henson_md @ASCOPost @VanitaNoronha @tmhmedoncalumni @DrEzraCohen @H_N_C_I_G Very important paper for our country. NACT with triplet is the treatment of choice in borderline resectable as defined in paper. Congratulations.

@todrashish Congratulations sir

@TuttsAkhil @ASCO @batraatulmd Beyond doubt, the most applicable study globally. Congratulations once again.

RT @davidhenrymd: #Metronomic #Chemotherapy performs well in second-line head and neck #Cancer 👉 @MDedgeHemOnc @Jimk…

#NewProfilePic

@adidhanawat @SuyogCancer @IJMPOofficial @ASCO @ONCOassist @AaronGoodman33 @montypal @neerajaiims #ASCO23

Pleasant surprise @CRSF_IN @NarayanaHealth